Rasha Aboelhassan: TOPAZ study has discovered a new line of treatment that significantly improves overall and progression-free survival
Rasha Aboelhassan, Nasser Institute Hospital, shared on LinkedIn:
“Biliary tract cancer is a challenging disease with very low survival rates.
However, the TOPAZ study has discovered a new line of treatment that significantly improves overall and progression-free survival.
Unfortunately, this treatment is not accessible to many patients due to its high cost.
To encourage early screening and select the right patients for effective treatment, a multidisciplinary team-based decision is needed.
Yesterday, I had the opportunity to meet with the highly professional team of GIT diseases headed by Prof Waleed Abdelaty from Nasser Institute to discuss the unmet needs of biliary tract cancer and conduct the first MDT for this challenging disease.
Let’s work together to improve access to effective treatment for all patients.
Thanks for Sherif Waguih and all AstraZeneca team of Egypt.
Heidi Nasr, thanks for your efforts and for your team support.”
Source: Rasha Aboelhassan/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023